Tiziana Life Sciences Plans to Spin Out Asset as Separate Company
By Freddy Sebastian
Tiziana Life Sciences said it's planning to develop an antibody that blocks a critical inflammatory pathway via a spinout into a separate publicly-traded company.
The biotech company said the decision was based in part on heightened industry interest in the interleukin-6 receptor pathway, underscored by Novartis' recent $1.4 billion acquisition of Tourmaline Bio.
In September, Novartis said the deal would boost its cardiovascular drug pipeline with access to the targeted therapy drug, pacibekitug.
Tiziana Life Sciences considers the antibody, known as TZLS-501, to have potential to operate as a standalone business and intends to proceed with steps for a publicly-listed immunology-focused spinout company, centered on the interleukin-6 receptor market.
The record date for the proposed spinoff will be announced in the coming weeks, the company said, and shareholder approval will also be sought.
"TZLS-501's unique dual mechanism--blocking IL-6R signaling while reducing circulating IL-6 cytokines--offers significant potential as a monotherapy or in combination with other agents," said Chief Executive Ivor Elrifi.
"This spin-out will unlock dedicated resources for its development, while allowing us to maintain focus on intranasal foralumab as our lead program."
Shares of the company fell 5.% to $1.70 in premarket trading Tuesday.
Write to Freddy Sebastian at freddy.sebastian@wsj.com
(END) Dow Jones Newswires
December 02, 2025 07:52 ET (12:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States